menu
    • menu
    [{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Oncology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Oncology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Active and Innovative","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Active and Innovative","highestDevelopmentStatusID":"11","companyTruncated":"University of Toronto \/ Active and Innovative"},{"orgOrder":0,"company":"Stearacl Inc","sponsor":"Reinhold Vieth","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Undisclosed","graph2":"Phase II","graph3":"Stearacl Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stearacl Inc \/ Reinhold Vieth","highestDevelopmentStatusID":"8","companyTruncated":"Stearacl Inc \/ Reinhold Vieth"},{"orgOrder":0,"company":"GSK","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Camphor","moa":"||TRPV1","graph1":"Neurology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Angelini Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Menthol

    Menu

    Menthol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stearacl Inc

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Stearacl Inc

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menthol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Reinhold Vieth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TOPICAL MENTHOL FOR TEAR SECRETION

                            Details : Menthol is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 07, 2025

                            Lead Product(s) : Menthol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Reinhold Vieth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innocan Pharma

                            Israel arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Camphor,Menthol

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Research Capital Corporation

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Closing of Second and Final Tranche of Financing

                            Details : The Company intends to use the net proceeds to fund the Company's pre-investigational new drug meeting regarding the human application of the Company's products, including Cannabidiol.

                            Product Name : LPT-CBD

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 20, 2023

                            Lead Product(s) : Cannabidiol,Camphor,Menthol

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Research Capital Corporation

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innocan Pharma

                            Israel arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Camphor,Menthol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Research Capital Corporation

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update

                            Details : The Company intends to use the net proceeds from the Offering to fund the Company's pre-investigational new drug meeting with the United States FDA regarding the human application and expansion of the Company's derma-cosmetic product distribution.

                            Product Name : LPT-CBD

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 12, 2023

                            Lead Product(s) : Cannabidiol,Camphor,Menthol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Research Capital Corporation

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GSK

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Camphor,Capsicum Oleoresin,Menthol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Angelini Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Angelini Pharma Acquires ThermaCare® From GSK

                            Details : The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence.

                            Product Name : ThermaCare

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 10, 2020

                            Lead Product(s) : Camphor,Capsicum Oleoresin,Menthol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Angelini Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of Toronto

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Toronto

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menthol

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Active and Innovative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MuscleCare™ Pain Relief Therapy vs. Voltaren® in the Relief of Trapezius Trigger Point Musculoskeleta...

                            Details : Menthol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2019

                            Lead Product(s) : Menthol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Active and Innovative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sandoz B2B

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sandoz B2B

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menthol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® ...

                            Details : Menthol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pharyngitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2017

                            Lead Product(s) : Menthol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sandoz B2B

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sandoz B2B

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menthol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ...

                            Details : Menthol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pharyngitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2017

                            Lead Product(s) : Menthol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menthol

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

                            Details : Menthol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 08, 2011

                            Lead Product(s) : Menthol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menthol

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

                            Details : Menthol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 08, 2011

                            Lead Product(s) : Menthol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth